BTAI
BTAI
NASDAQ · Biotechnology

Bioxcel Therapeutics Inc

$1.23
-0.11 (-8.21%)
As of Apr 1, 3:51 PM ET ·
Financial Highlights (FY 2026)
Revenue
23.12M
Net Income
-607,977,939
Gross Margin
5.4%
Profit Margin
-2,630.1%
Rev Growth
D/E Ratio
1.21
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 5.4% 67.3% 67.3% 67.3%
Operating Margin -2,967.6% -11.4% -12.1% -10.8%
Profit Margin -2,630.1% -10.0% -10.7% -10.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 23.12M 6.05M 5.52M 6.67M
Gross Profit 1.26M 4.07M 3.71M 4.49M
Operating Income -685,984,641 -692,499 -670,275 -720,471
Net Income -607,977,939 -605,390 -589,967 -686,380
Gross Margin 5.4% 67.3% 67.3% 67.3%
Operating Margin -2,967.6% -11.4% -12.1% -10.8%
Profit Margin -2,630.1% -10.0% -10.7% -10.3%
Rev Growth +6.5% -1.7% -4.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 9.14M 6.86M 5.54M 6.52M
Total Equity 7.54M 26.63M 24.64M 23.32M
D/E Ratio 1.21 0.26 0.23 0.28
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -477,034,016 -1,010,044 -924,468 -1,114,371
Free Cash Flow -597,812 -774,673 -818,976